Department of Internal Medicine, Division of Medical Genetics, University of Texas Health Science Center at Houston, Houston, Texas 77030, USA.
J Clin Invest. 2013 Sep;123(9):3777-87. doi: 10.1172/JCI69091. Epub 2013 Aug 27.
The autosomal dominantly inherited east Texas bleeding disorder is linked to an A2440G variant in exon 13 of the F5 gene. Affected individuals have normal levels of coagulation factor V (FV) activity, but demonstrate inhibition of global coagulation tests. We demonstrated that the A2440G mutation causes upregulation of an alternatively spliced F5 transcript that results in an in-frame deletion of 702 amino acids of the large activation fragment, the B domain. The approximately 250-kDa FV isoform (FV-short), which can be fully activated by thrombin, is present in all A2440G carriers' plasma (n = 16). FV-short inhibits coagulation through an indirect mechanism by forming a complex with tissue factor pathway inhibitor-α (TFPIα), resulting in an approximately 10-fold increase in plasma TFPIα, suggesting that the TFPIα:FV-short complexes are retained in circulation. The TFPIα:FV-short complexes efficiently inhibit thrombin generation of both intrinsic and extrinsic coagulation pathways. These data demonstrate that the east Texas bleeding disorder-associated F5(A2440G) leads to the formation of the TFPIα:FV-short complex, which inhibits activation and propagation of coagulation.
常染色体显性遗传的德克萨斯州东部出血性疾病与 F5 基因第 13 外显子的 A2440G 变体相关。受影响的个体具有正常水平的凝血因子 V(FV)活性,但表现出对整体凝血测试的抑制。我们证明,A2440G 突变导致异常剪接的 F5 转录本上调,从而导致大激活片段(B 域)的 702 个氨基酸缺失。大约 250 kDa 的 FV 同种型(FV-short)可被凝血酶完全激活,存在于所有 A2440G 携带者的血浆中(n = 16)。FV-short 通过与组织因子途径抑制剂-α(TFPIα)形成复合物,通过间接机制抑制凝血,导致血浆 TFPIα 增加约 10 倍,这表明 TFPIα:FV-short 复合物保留在循环中。TFPIα:FV-short 复合物可有效抑制内源性和外源性凝血途径的凝血酶生成。这些数据表明,与德克萨斯州东部出血性疾病相关的 F5(A2440G)导致 TFPIα:FV-short 复合物的形成,从而抑制凝血的激活和传播。